As 2024 draws to a close, we’re celebrating a great year of content.
In this video Dr Nico Gagelmann and Dr Claire Horgan co-chairs delve into the objectives of the EBMT Trainee Committee in fostering collaboration, harmonizing training and enhancing access to education for hematology trainees across Europe and beyond.
Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
In this interview, Prof. Pierre Fenaux, discusses key considerations for first-line therapies in lower-risk MDS, the latest advances in treatment and the role of organizations like the European School of Hematology (ESH) in supporting haematologists.
Education, Conference Coverage and Articles
Watch this touchCONGRESS activity exploring advances in treatments for patients with CML, based on data from 2024 congresses, including EHA and ESH-iCMLf.
In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms (MPNs). In this episode, we speak with John Mascarenhas, MD, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.
Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.
Share your knowledge, influence clinical practices and enhance patient care in Haematology today!
“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were ...
Histone-lysine N-methyltransferase 2A rearrangements (KMT2Ar) and mutant nucleophosmin 1 (mNPM1) occur in approximately 5–10% and 30% of patients with acute myeloid leukaemia (AML), respectively.1,2 Both mutations are associated with the founding events in the development of leukaemia.1 In particular, KMT2Ar functions ...
Frontline treatment with azacitidine plus venetoclax (AZA/VEN) significantly improved remission rates and survival duration for older, frail and high-risk patients with acute myeloid leukaemia (AML) in the pivotal VIALE-A trial.1 The combination is approved for use in this setting,2 ...
Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.
Two specialists in chronic myeloid leukaemia (CML) discuss the mechanisms of action and latest data for current and emerging treatments and how they may impact the management of CML after two prior lines of therapy.
Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.
Three experts consider the potential of immune-based strategies to treat MDS and AML.
Watch this two-part activity exploring recent developments in the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA 2022 Hybrid Congress.
Watch this two-part activity exploring recent data on current and emerging treatments for CML. Filmed following the EHA Hybrid Conference 2022.
Watch chronic myeloid leukaemia (CML) specialists within a multidisciplinary team, plus a CML patient advocate, discuss the later-line management of CML.
Watch this two-part activity exploring recent data on new and emerging treatments for patients with higher-risk MDS and newly diagnosed AML, filmed following the ASH 2021 Annual Meeting & Exposition.
Watch leading experts review adverse event management with BCMA-targeting multiple myeloma therapies, and consider the role of the multidisciplinary team.
Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.
Introducing the Expert Faculty of touchHAEMATOLOGY, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.
Myelodysplastic Syndrome
Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, USA
Dr John Mascarenhas is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. Dr Mascarenhas is the Director of Center of Excellence in Blood Cancers and Myeloid Disorders, Director of the Adult Leukemia Program, and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai. As a clinical investigator in malignant hematology with a focus in translational research involving MPNs, he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary acute leukemia.
Coagulation, thrombotic events
Full Professor and Deputy Head of the Department of Clinical Pharmacology at the Medical University of Vienna, Vienna, Austria
Bernd Jilma, MD, is a Full Professor and Deputy Head of the Department of Clinical Pharmacology at the Medical University of Vienna. His scientific interests encompass coagulation research, anaphylaxis, rare diseases, biologics, and vaccines. Since 2001, Dr. Jilma has been a principal investigator in phase I, II, and III clinical trials, including multinational studies. He has published over 525 peer-reviewed articles in esteemed journals such as NEJM, Lancet, Lancet Infect Dis, JACC, Blood, Circulation, and Am J Respir Crit Care Med.
Thrombosis
Hematologist, Division of Hematology at Washington University School of Medicine St. Louis and Staff Physician, Division of Hematology/Oncology at John Cochran Veterans Administration Medical Center, St. Louis, MO, USA
Dr. Kristen Sanfilippo is a Hematologist in the Division of Hematology at Washington University School of Medicine St. Louis and a Staff Physician in the Division of Hematology/Oncology at John Cochran Veterans Administration Medical Center St. Louis, USA. She is a co-chair of the International Society on thrombosis and Haemostasis Scientific and Standardization Committee for Hemostasis and Malignancy. In addition to clinical training in hematology/oncology, she earned a Masters in Population Health Sciences at Washington University St. Louis School of Medicine in 2012. Since completion of her Master’s degree, Dr. Sanfilippo has focused her research on health outcomes in patients with venous thromboembolism with a focus on cancer-associated thrombosis. Her research group developed and validated a risk prediction model, IMPEDE VTE, to identify patients with multiple myeloma starting chemotherapy at high-risk of venous thromboembolism. In addition, through a collaboration with a research team at University of Washington School of Medicine, they developed the SAVED score to predict risk of venous thromboembolism in multiple myeloma patients receiving an immunomodulatory agent. Both IMPEDE VTE and the SAVED score are recommended as the risk prediction models of choice by the National Comprehensive Cancer Network (NCCN) clinical guidelines. Her clinical and research interests continue to focus on venous thromboembolism and cancer-associated thrombosis with her current work focused on understanding risk-factors for anticoagulant-related bleeding in patients with cancer.
Leukaemia
Nurse Manager at University Hospital Zürich, Zürich, Switzerland
Erik Aerts is a Nurse Manager at University Hospital Zürich in Zürich, Switzerland, where he leads the nursing operations in the Department of Medicine Oncology and Haematology. He pioneered the first haematology-oncology nursing course in Switzerland, providing nurses with the opportunity to specialize in haematology and oncology. With 30 years of nursing experience across diverse settings and specialties, his focus has been on haematology and haematopoietic stem cell transplantation (HSCT).
Mr. Aerts also serves as President of several professional groups, including the Haematology Nurses & Healthcare Professionals Group and the European Group for Blood and Marrow Transplantation Nurses Group.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.